{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:49:02Z","timestamp":1791499742016,"version":"4.3.4"},"reference-count":194,"publisher":"Elsevier BV","issue":"10523","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/s0140-6736(25)01942-7","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T23:55:40Z","timestamp":1764114940000},"page":"90-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Chronic kidney disease"],"prefix":"10.1016","volume":"407","author":[{"given":"William G","family":"Herrington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parminder K","family":"Judge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan E","family":"Grams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl","key":"10.1016\/S0140-6736(25)01942-7_bib1","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(05)17789-7","article-title":"Chronic kidney disease: the global challenge","volume":"365","author":"Meguid El Nahas","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(11)60178-5","article-title":"Chronic kidney disease","volume":"379","author":"Levey","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib4","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib5","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"Kalantar-Zadeh","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib6","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/S0140-6736(25)01942-7_bib8","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib11","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial","volume":"12","author":"Judge","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-KIDNEY trial","volume":"12","author":"Staplin","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib16","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib17","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib19","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib20","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in Patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib21","author":"US"},{"key":"10.1016\/S0140-6736(25)01942-7_bib22","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/S0140-6736(25)01942-7_bib23","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib26","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/ndt\/gfae132","article-title":"Design and baseline characteristics of the finerenone, in addition to standard of care, on the progression of kidney disease in patients with non-diabetic chronic kidney disease (FIND-CKD) randomized trial","volume":"40","author":"Heerspink","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/S0140-6736(25)01942-7_bib27","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/ndt\/gfae263","article-title":"The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial","volume":"40","author":"Judge","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 7","key":"10.1016\/S0140-6736(25)01942-7_bib29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/dom.15921","article-title":"Continuous ketone monitoring: exciting implications for clinical practice","volume":"26","author":"Kong","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/S0140-6736(25)01942-7_bib30","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.kint.2022.03.019","article-title":"Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference","volume":"101","author":"K\u00f6ttgen","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib35","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/S0140-6736(25)00548-3","article-title":"Reducing the burden of chronic kidney disease in the world","volume":"405","author":"Lou-Meda","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib36","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Grams","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/S0140-6736(25)01942-7_bib37","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/ndt\/gfz174","article-title":"A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases","volume":"34","author":"Jager","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/S0140-6736(25)01942-7_bib38","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.ASN.0000100125.21491.46","article-title":"The number, quality, and coverage of randomized controlled trials in nephrology","volume":"15","author":"Strippoli","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib39","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1053\/j.ajkd.2013.10.043","article-title":"The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov","volume":"63","author":"Inrig","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/S0140-6736(25)01942-7_bib40","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.kint.2017.04.019","article-title":"Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference","volume":"92","author":"Baigent","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib41","doi-asserted-by":"crossref","first-page":"e1003954","DOI":"10.1371\/journal.pmed.1003954","article-title":"Symptom burden and health-related quality of life in chronic kidney disease: a global systematic review and meta-analysis","volume":"19","author":"Fletcher","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib42","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ki.2015.230","article-title":"A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010","volume":"88","author":"Mills","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib43","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.1016\/S2214-109X(23)00570-3","article-title":"An update on the global disparities in kidney disease burden and care across world countries and regions","volume":"12","author":"Bello","year":"2024","journal-title":"Lancet Glob Health"},{"key":"10.1016\/S0140-6736(25)01942-7_bib44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.kint.2020.10.012","article-title":"The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"99","author":"Shlipak","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib45","doi-asserted-by":"crossref","first-page":"e000728","DOI":"10.1136\/bmjgh-2018-000728","article-title":"Chronic kidney disease care models in low- and middle-income countries: a systematic review","volume":"3","author":"Stanifer","year":"2018","journal-title":"BMJ Glob Health"},{"key":"10.1016\/S0140-6736(25)01942-7_bib46","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/ANNALS-24-01926","article-title":"Evaluation and management of chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2024 clinical practice guideline","volume":"178","author":"Madero","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000509359","article-title":"Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference","volume":"6","author":"Levey","year":"2020","journal-title":"Kidney Dis"},{"key":"10.1016\/S0140-6736(25)01942-7_bib48","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib49","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib50","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ndt\/gfac254","article-title":"What should European nephrology do with the new CKD-EPI equation?","volume":"38","author":"Gansevoort","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/S0140-6736(25)01942-7_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/HYHN1078","article-title":"Accuracy of glomerular filtration rate estimation using creatinine and cystatin C for identifying and monitoring moderate chronic kidney disease: the eGFR-C study","volume":"28","author":"Lamb","year":"2024","journal-title":"Health Technol Assess"},{"key":"10.1016\/S0140-6736(25)01942-7_bib53","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/jcsm.13511","article-title":"Creatinine, cystatin C, muscle mass, and mortality: findings from a primary and replication population-based cohort","volume":"15","author":"Groothof","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/S0140-6736(25)01942-7_bib54","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1053\/j.ackd.2017.09.003","article-title":"Measured GFR in routine clinical practice-the promise of dried blood spots","volume":"25","author":"Bjornstad","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/S0140-6736(25)01942-7_bib55","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.ajkd.2021.04.016","article-title":"Measurement and Estimation of GFR for use in clinical practice: core curriculum 2021","volume":"78","author":"Inker","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/S0140-6736(25)01942-7_bib56","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment","volume":"28","author":"Tonneijck","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib57","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/S0140-6736(25)01942-7_bib58","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/ndt\/gfw396","article-title":"Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection","volume":"33","author":"Mafham","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/S0140-6736(25)01942-7_bib59","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1681\/ASN.2008030292","article-title":"First morning voids are more reliable than spot urine samples to assess microalbuminuria","volume":"20","author":"Witte","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib60","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Bikbov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib61","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.ajkd.2020.11.026","article-title":"CKD progression and mortality among men and women: a nationwide study in Sweden","volume":"78","author":"Swartling","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/S0140-6736(25)01942-7_bib62","doi-asserted-by":"crossref","first-page":"sfae044","DOI":"10.1093\/ckj\/sfae044","article-title":"Sex disparities in mortality and cardiovascular outcomes in chronic kidney disease","volume":"17","author":"Balafa","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/S0140-6736(25)01942-7_bib64","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","article-title":"Chronic kidney disease and the global public health agenda: an international consensus","volume":"20","author":"Francis","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib65","doi-asserted-by":"crossref","first-page":"e0003979","DOI":"10.1371\/journal.pgph.0003979","article-title":"Landscape of kidney replacement therapy provision in low- and lower-middle income countries: a multinational study from the ISN-GKHA","volume":"4","author":"Nkunu","year":"2024","journal-title":"PLOS Glob Public Health"},{"key":"10.1016\/S0140-6736(25)01942-7_bib66","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/S0140-6736(24)00685-8","article-title":"Burden of disease scenarios for 204 countries and territories, 2022\u20132050: a forecasting analysis for the Global Burden of Disease Study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib67","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib68","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41581-022-00618-4","article-title":"Impact of the COVID-19 pandemic on the kidney community: lessons learned and future directions","volume":"18","author":"Geetha","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib69","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ki.2013.153","article-title":"Raising awareness of acute kidney injury: a global perspective of a silent killer","volume":"84","author":"Lewington","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib70","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrneph.2013.36","article-title":"Community-acquired acute kidney injury in tropical countries","volume":"9","author":"Jha","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib71","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.ajkd.2013.12.013","article-title":"Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP)","volume":"64","author":"Haynes","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/S0140-6736(25)01942-7_bib72","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib73","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib74","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib75","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib76","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/ki.1996.265","article-title":"The hyperfiltration theory: a paradigm shift in nephrology","volume":"49","author":"Brenner","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib77","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib79","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3109\/0886022X.2013.794683","article-title":"Correlation of kidney size with kidney function and anthropometric parameters in healthy subjects and patients with chronic kidney diseases","volume":"35","author":"Jovanovi\u0107","year":"2013","journal-title":"Ren Fail"},{"key":"10.1016\/S0140-6736(25)01942-7_bib80","doi-asserted-by":"crossref","first-page":"100435","DOI":"10.1016\/j.xkme.2022.100435","article-title":"Emerging role of clinical genetics in CKD","volume":"4","author":"Devarajan","year":"2022","journal-title":"Kidney Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib81","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2024.07.009","article-title":"KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD)","volume":"107","author":"Devuyst","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib82","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.kint.2024.11.013","article-title":"Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"107","author":"Ketteler","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib83","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"113","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/S0140-6736(25)01942-7_bib84","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.kint.2023.05.009","article-title":"Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"104","author":"Ku","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib85","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/j.ajkd.2019.05.032","article-title":"CKD in China: evolving spectrum and public health implications","volume":"76","author":"Yang","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/S0140-6736(25)01942-7_bib86","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.ekir.2023.02.1082","article-title":"Unmet needs of CKD in Latin America: a review from expert virtual working group","volume":"8","author":"Correa-Rotter","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/S0140-6736(25)01942-7_bib87","doi-asserted-by":"crossref","first-page":"e1632","DOI":"10.1016\/S2214-109X(19)30443-7","article-title":"Kidney damage and associated risk factors in rural and urban sub-Saharan Africa (AWI-Gen): a cross-sectional population study","volume":"7","author":"George","year":"2019","journal-title":"Lancet Glob Health"},{"key":"10.1016\/S0140-6736(25)01942-7_bib88","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/ckj\/sfab149","article-title":"The Indian Chronic Kidney Disease (ICKD) study: baseline characteristics","volume":"15","author":"Kumar","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/S0140-6736(25)01942-7_bib89","doi-asserted-by":"crossref","first-page":"e015069","DOI":"10.1136\/bmjopen-2016-015069","article-title":"Prevalence and burden of chronic kidney disease among the general population and high-risk groups in Africa: a systematic review","volume":"8","author":"Abd ElHafeez","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/S0140-6736(25)01942-7_bib90","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2404211","article-title":"APOL1 bi- and monoallelic variants and chronic kidney disease in West Africans","volume":"392","author":"Gbadegesin","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib91","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/ndt\/gfad052","article-title":"The complex pathology of diabetic nephropathy in humans","volume":"38","author":"Kriz","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/S0140-6736(25)01942-7_bib92","doi-asserted-by":"crossref","first-page":"F600","DOI":"10.1152\/ajprenal.00669.2020","article-title":"Pathomorphological sequence of nephron loss in diabetic nephropathy","volume":"321","author":"L\u00f6wen","year":"2021","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib93","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.2337\/dc19-0349","article-title":"Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function-even without albuminuria","volume":"42","author":"Vistisen","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/S0140-6736(25)01942-7_bib94","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib95","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.kint.2020.04.044","article-title":"A bidirectional Mendelian randomization study supports causal effects of kidney function on blood pressure","volume":"98","author":"Yu","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib96","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1806891","article-title":"Diagnostic utility of exome sequencing for kidney disease","volume":"380","author":"Groopman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib97","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/ckj\/sfaa162","article-title":"Hypertensive nephropathy: a major roadblock hindering the advance of precision nephrology","volume":"13","author":"Carriazo","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/S0140-6736(25)01942-7_bib99","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(23)02843-X","article-title":"Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort","volume":"403","author":"Wong","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib100","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1053\/j.ajkd.2018.06.008","article-title":"Untangling Mesoamerican nephropathy","volume":"72","author":"Aguilar-Ramirez","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/S0140-6736(25)01942-7_bib101","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12882-022-02861-0","article-title":"High prevalence of chronic kidney disease of unknown etiology among workers in the Mesoamerican Nephropathy Occupational Study","volume":"23","author":"Keogh","year":"2022","journal-title":"BMC Nephrol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib102","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jama.2011.451","article-title":"A predictive model for progression of chronic kidney disease to kidney failure","volume":"305","author":"Tangri","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/S0140-6736(25)01942-7_bib103","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2015.18202","article-title":"Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis","volume":"315","author":"Tangri","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/S0140-6736(25)01942-7_bib104","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ki.2011.223","article-title":"Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"80","author":"Herzog","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib105","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.kint.2019.02.022","article-title":"Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"House","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib106","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.kint.2021.04.029","article-title":"Central and peripheral arterial diseases in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"100","author":"Johansen","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib107","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/eurheartj\/ehy060","article-title":"Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"39","author":"Turakhia","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/S0140-6736(25)01942-7_bib108","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1161\/STROKEAHA.120.029680","article-title":"Chronic kidney disease and cerebrovascular disease: consensus and guidance from a KDIGO Controversies Conference","volume":"52","author":"Kelly","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/S0140-6736(25)01942-7_bib109","doi-asserted-by":"crossref","first-page":"f324","DOI":"10.1136\/bmj.f324","article-title":"Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis","volume":"346","author":"Nitsch","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/S0140-6736(25)01942-7_bib110","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/ki.2013.553","article-title":"Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar","volume":"86","author":"Wen","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib111","doi-asserted-by":"crossref","first-page":"100552","DOI":"10.1016\/j.eclinm.2020.100552","article-title":"Incorporating kidney disease measures into cardiovascular risk prediction: development and validation in 9 million adults from 72 datasets","volume":"27","author":"Matsushita","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/S0140-6736(25)01942-7_bib112","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association's PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/S0140-6736(25)01942-7_bib113","first-page":"CD013119","article-title":"Interventions for weight loss in people with chronic kidney disease who are overweight or obese","volume":"3","author":"Conley","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/S0140-6736(25)01942-7_bib114","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S2213-8587(14)70156-1","article-title":"Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial","volume":"2","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib115","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/S0140-6736(25)01942-7_bib116","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/S0140-6736(25)01942-7_bib117","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 Clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib118","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1161\/HYPERTENSIONAHA.117.10479","article-title":"Blood pressure measurement in SPRINT (Systolic Blood Pressure Intervention Trial)","volume":"71","author":"Johnson","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/S0140-6736(25)01942-7_bib119","doi-asserted-by":"crossref","first-page":"f5680","DOI":"10.1136\/bmj.f5680","article-title":"Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials","volume":"347","author":"Ninomiya","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/S0140-6736(25)01942-7_bib120","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib121","first-page":"CD010070","article-title":"Altered dietary salt intake for people with chronic kidney disease","volume":"6","author":"McMahon","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/S0140-6736(25)01942-7_bib122","doi-asserted-by":"crossref","first-page":"F262","DOI":"10.1152\/ajprenal.00099.2005","article-title":"Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences","volume":"290","author":"Vaziri","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib123","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2215\/CJN.03390807","article-title":"Lipoprotein abnormalities associated with mild impairment of kidney function in the multi-ethnic study of atherosclerosis","volume":"3","author":"de Boer","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1542-4758.2006.01168.x","article-title":"Mechanisms of dyslipidemia of chronic renal failure","volume":"10","author":"Vaziri","year":"2006","journal-title":"Hemodial Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib125","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials","volume":"4","author":"Herrington","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib126","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib127","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib128","first-page":"259","article-title":"KDIGO clinical practice guideline for lipid management in chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/S0140-6736(25)01942-7_bib129","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12944-023-01833-z","article-title":"International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care: is it time to review guideline recommendations?","volume":"22","author":"Calice-Silva","year":"2023","journal-title":"Lipids Health Dis"},{"key":"10.1016\/S0140-6736(25)01942-7_bib130","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1001\/archinte.168.22.2449","article-title":"Effect of a Mediterranean diet supplemented with nuts on metabolic syndrome status: one-year results of the PREDIMED randomized trial","volume":"168","author":"Salas-Salvad\u00f3","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib131","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0140-6736(22)00122-2","article-title":"Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial","volume":"399","author":"Delgado-Lista","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib132","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib133","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1053\/j.ajkd.2004.08.020","article-title":"High-protein diets: potential effects on the kidney in renal health and disease","volume":"44","author":"Friedman","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/S0140-6736(25)01942-7_bib134","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib135","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib136","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib137","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib138","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2337\/dc06-1998","article-title":"Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes","volume":"30","author":"Makino","year":"2007","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"10.1016\/S0140-6736(25)01942-7_bib139","first-page":"S239","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes-2025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/S0140-6736(25)01942-7_bib140","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(25)00222-0","article-title":"Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis","author":"Herrington","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib142","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2409183","article-title":"Long-term effects of empagliflozin in patients with chronic kidney disease","volume":"392","author":"Herrington","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib143","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/S0140-6736(25)01942-7_bib144","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1007\/s11606-021-07311-5","article-title":"Cost-effectiveness of dapagliflozin for non-diabetic chronic kidney disease","volume":"37","author":"Tisdale","year":"2022","journal-title":"J Gen Intern Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib145","doi-asserted-by":"crossref","first-page":"103338","DOI":"10.1016\/j.eclinm.2025.103338","article-title":"Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial","volume":"85","author":"Zhou","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/S0140-6736(25)01942-7_bib146","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib147","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S2213-8587(23)00168-7","article-title":"People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action","volume":"11","author":"Heerspink","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib148","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfaf061","article-title":"SGLT2 inhibition for patients with ADPKD - closing the evidence gap","author":"M\u00fcller","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/S0140-6736(25)01942-7_bib149","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jacc.2024.10.091","article-title":"Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF trial","volume":"85","author":"Mc Causland","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib150","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib151","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib152","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib153","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1111\/dom.15058","article-title":"Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and\/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial","volume":"25","author":"McGuire","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/S0140-6736(25)01942-7_bib154","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib155","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S2213-8587(17)30104-3","article-title":"Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials","volume":"5","author":"Zoungas","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib156","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","article-title":"Intensive glucose control and macrovascular outcomes in type 2 diabetes","volume":"52","author":"Turnbull","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/S0140-6736(25)01942-7_bib157","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(24)00537-3","article-title":"Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91)","volume":"404","author":"Adler","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib158","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","article-title":"Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes","volume":"60","author":"Griffin","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/S0140-6736(25)01942-7_bib159","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40262-013-0046-9","article-title":"Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function","volume":"52","author":"Duong","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib160","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","article-title":"Clinical pharmacokinetics of metformin","volume":"50","author":"Graham","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib161","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","article-title":"A meta-analysis of GFR slope as a surrogate endpoint for kidney failure","volume":"29","author":"Inker","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib162","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.kint.2025.01.014","article-title":"Treatment of patients with IgA nephropathy: a call for a new paradigm","volume":"107","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib163","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib164","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(25)01942-7_bib165","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib166","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa2308550","article-title":"Sparsentan versus irbesartan in focal segmental glomerulosclerosis","volume":"389","author":"Rheault","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib167","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib168","author":"US"},{"key":"10.1016\/S0140-6736(25)01942-7_bib169","author":"US"},{"key":"10.1016\/S0140-6736(25)01942-7_bib170","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib171","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.kint.2024.07.010","article-title":"KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary","volume":"107","author":"Torres","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib172","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S2213-8587(23)00253-X","article-title":"Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"11","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib173","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib174","first-page":"1120","article-title":"Meta-analysis of intravascular volume expansion strategies to prevent contrast-associated acute kidney injury following invasive angiography","volume":"98","author":"Michel","year":"2021","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/S0140-6736(25)01942-7_bib175","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.xkme.2020.01.001","article-title":"Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation","volume":"2","author":"Davenport","year":"2020","journal-title":"Kidney Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib176","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.amjcard.2013.08.040","article-title":"Meta-analysis of the effect of automated contrast injection devices versus manual injection and contrast volume on risk of contrast-induced nephropathy","volume":"113","author":"Minsinger","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib177","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.ajkd.2018.08.013","article-title":"Relationship of estimated GFR and albuminuria to concurrent laboratory abnormalities: an individual participant data meta-analysis in a global consortium","volume":"73","author":"Inker","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/S0140-6736(25)01942-7_bib178","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) guideline update: what's changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib179","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","article-title":"Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference","volume":"99","author":"Babitt","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib180","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib181","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib182","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib183","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the treatment of anemia in patients undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib184","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib185","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12882-023-03339-3","article-title":"UK Kidney Association clinical practice guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease 2023 update","volume":"24","author":"Roddick","year":"2023","journal-title":"BMC Nephrol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib186","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1093\/ndt\/gfad112","article-title":"SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA","volume":"38","author":"Mark","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/S0140-6736(25)01942-7_bib187","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/S0140-6736(25)01942-7_bib188","first-page":"CD014906","article-title":"Protein restriction for diabetic kidney disease","volume":"1","author":"Jiang","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/S0140-6736(25)01942-7_bib189","first-page":"CD001892","article-title":"Low protein diets for non-diabetic adults with chronic kidney disease","volume":"10","author":"Hahn","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl 1","key":"10.1016\/S0140-6736(25)01942-7_bib190","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","article-title":"KDOQI clinical practice guideline for nutrition in CKD: 2020 update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/S0140-6736(25)01942-7_bib191","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1053\/j.ajkd.2024.08.003","article-title":"KDOQI US commentary on the KDIGO 2024 clinical practice guideline for the evaluation and management of CKD","volume":"85","author":"Navaneethan","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/S0140-6736(25)01942-7_bib192","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","article-title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials","volume":"12","author":"Apperloo","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib193","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/S0140-6736(25)01942-7_bib194","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.14558","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: a subgroup analysis from the FIDELIO-DKD trial","volume":"24","author":"Rossing","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/S0140-6736(25)01942-7_bib195","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib196","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/CIRCULATIONAHA.123.068524","article-title":"Accelerated risk-based implementation of guideline-directed medical therapy for type 2 diabetes and chronic kidney disease","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/S0140-6736(25)01942-7_bib197","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/S0140-6736(25)01942-7_bib198","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib7","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib9","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)01942-7_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"suppl 1","key":"10.1016\/S0140-6736(25)01942-7_bib28","doi-asserted-by":"crossref","first-page":"i47","DOI":"10.1093\/ndt\/gfae216","article-title":"Upcoming drug targets for kidney protective effects in chronic kidney disease","volume":"40","author":"Nardone","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 1","key":"10.1016\/S0140-6736(25)01942-7_bib31","doi-asserted-by":"crossref","first-page":"i70","DOI":"10.1093\/ndt\/gfae210","article-title":"Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease","volume":"40","author":"Zhu","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/S0140-6736(25)01942-7_bib32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41581-019-0212-x","article-title":"Kidney disease trials for the 21st century: innovations in design and conduct","volume":"16","author":"Herrington","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/S0140-6736(25)01942-7_bib33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13023-025-03634-2","article-title":"Debates over orphan drug pricing: a meta-narrative literature review","volume":"20","author":"Hanchard","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/S0140-6736(25)01942-7_bib34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.kint.2025.04.005","article-title":"Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"108","author":"Ortiz","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/S0140-6736(25)01942-7_bib78","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.kint.2024.12.021","article-title":"The prevention and management of chronic kidney disease among patients with metabolic syndrome","volume":"107","author":"Zhu","year":"2025","journal-title":"Kidney Int"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673625019427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673625019427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:22:02Z","timestamp":1767964922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673625019427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":194,"journal-issue":{"issue":"10523","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0140673625019427"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(25)01942-7","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"The Lancet","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(25)01942-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}